Cary Street Partners Financial LLC Invests $4.74 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Cary Street Partners Financial LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 99,154 shares of the biopharmaceutical company's stock, valued at approximately $4,741,000. Cary Street Partners Financial LLC owned about 0.08% of Halozyme Therapeutics as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 197 shares during the last quarter. Louisiana State Employees Retirement System grew its position in Halozyme Therapeutics by 0.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock worth $1,688,000 after purchasing an additional 200 shares in the last quarter. Baird Financial Group Inc. increased its stake in Halozyme Therapeutics by 2.0% in the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock valued at $532,000 after buying an additional 221 shares during the last quarter. CreativeOne Wealth LLC boosted its stake in shares of Halozyme Therapeutics by 1.6% in the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after buying an additional 294 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D grew its holdings in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock valued at $2,279,000 after acquiring an additional 302 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $60.62 on Tuesday. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a one year low of $40.19 and a one year high of $66.00. The firm has a market capitalization of $7.49 billion, a P/E ratio of 17.67, a PEG ratio of 0.42 and a beta of 1.26. The business has a fifty day moving average price of $60.85 and a 200-day moving average price of $55.46.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

HALO has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Benchmark reiterated a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $62.89.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 4,497 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director now directly owns 28,611 shares in the company, valued at $1,727,246.07. The trade was a 13.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,697 shares of company stock worth $1,276,552 in the last three months. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.